Peptides and neurodegeneration - the good, the bad, and the beautiful complexity of hope

Richard Moore
Nov 25, 2025
14 min read

Imagine that the next chapter in the fight against neurodegeneration does not begin with a blockbuster drug, but with something so small you could easily overlook it: a peptide. A peptide is a short chain of amino acids, a sliver of a protein, more like a keychain than a full set of keys. Because of its size, a peptide can slip through molecular doors that larger drugs cannot, entering tight spaces within cells and interacting with specific biochemical systems with remarkable precision (Muttenthaler et al., 2021).

In scientific circles, peptides have been rising quietly but steadily. Their name now appears in discussions about three of the most challenging neurological conditions we know: Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS), Parkinson’s disease, and Alzheimer’s disease (Zuccaro 2021). For people living with these conditions, the essential question remains: do peptides represent genuine hope - or are they simply another scientific buzzword?

To answer this meaningfully, we must treat the science like a detective story. And it begins with the smallest clues.

A detective story begins: following the peptide trial

One of the earliest clues emerged not from brain imaging or genetic sequencing, but from the liquid that surrounds the brain and spinal cord. In 2024, researchers analysing cerebrospinal fluid (CSF) from people with ALS discovered a distinct set of thirty-three peptides that differed consistently from those in healthy controls . These fragments formed a biochemical signature reflecting disruptions in metabolism, inflammation, and protein turnover (Lumi et al., 2024). In other words, the disease had begun revealing itself through peptides long before symptoms fully appeared.

Another important breadcrumb in this molecular mystery involves VGF nerve growth factor-inducible protein (VGF) - a neurotrophic protein crucial for neuronal resilience. Across ALS, Parkinson’s disease, and Alzheimer’s disease, multiple studies show that VGF-derived peptides are consistently reduced in CSF, blood, and brain tissue (Cocco et al., 2022; Scaricamazza et al., 2021). These declines correlate with disease stage and progression, suggesting VGF peptides act like faint distress signals emitted by struggling neurones.

Meanwhile, metabolic peptides such as neuropeptide Y (NPY), leptin, and peptide YY (PYY) also shift in ALS and frontotemporal dementia, closely mirroring changes in body weight, appetite, and metabolic rate (Ahmed et al., 2019). Together, these clues reveal just how early and subtly neurodegeneration begins altering peptide environments long before physical symptoms are noticeable.

But clues alone do not solve the case. The next revelation came when researchers discovered that peptides in neurodegeneration do not simply signal problems - they sometimes shape them.

The first big reveal: peptides can help - or harm

Some peptides act protectively. Pituitary adenylate cyclase-activating polypeptide (PACAP), a naturally occurring neuropeptide widely expressed throughout the nervous system, has demonstrated the ability to protect neurones from oxidative stress, inflammation, and apoptosis in preclinical amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease models (Cacabelos et al., 2021). It behaves like a biochemical first responder, arriving at the scene of neuronal injury and attempting stabilisation.

Other peptides, however, take a darker turn. Substance P, a neuropeptide involved in pain signalling, becomes dysregulated in ALS and may exacerbate inflammatory responses and microglial activation (Tirassa, 2024). Even more striking, a 2023 study found that unique peptides appearing only in ALS CSF - including fragments of transthyretin and osteopontin - triggered inflammatory toxicity when added to microglia and mouse models (Piras et al., 2023). These peptides did not merely reflect disease: they contributed to its pathology.

The detective story deepens: peptides are not all heroes. Some are suspects.

ALS: where peptides hold promise but demand humility

ALS carries enormous emotional weight. At present, no peptide has been shown in human clinical trials to slow or reverse ALS progression (Paganoni et al., 2020; van Eijk et al., 2017). Yet early peptide discoveries have generated moments of genuine scientific hope.

One breakthrough came in 2023, when researchers developed a cell-penetrating peptide that bound to and neutralised the toxic ribonucleic acid (RNA) repeats produced by the C9orf72 mutation, the leading genetic cause of ALS (Castelli et al., 2023). This peptide reduced harmful dipeptide repeat proteins and improved the survival of patient-derived neurones (Castelli et al., 2023) - the molecular equivalent of interrupting a villain mid-crime.

Because crossing the blood–brain barrier is difficult, scientists have explored alternative delivery routes. Research summarised by the Motor Neurone Disease Association described peptide delivery via the nasal passage in preclinical studies, allowing direct transport to the central nervous system (Motor Neurone Disease Association, 2023). This work remains experimental but suggests future therapeutic possibilities.

Not all peptide chapters contain triumphs. Zilucoplan, a complement-blocking peptide aimed at inhibiting complement component 5 (C5), underwent rigorous testing in the HEALEY ALS Platform Trial. The results revealed no significant effect on disease progression (van den Berg et al., 2023). Although disappointing for the ALS community, this trial was scientifically invaluable: it clarified that complement inhibition is not an effective therapeutic pathway in ALS.

In ALS, the peptide story is not yet one of cures. It is one of revelations, redirections, and emerging frontiers.

Parkinson’s disease: promise, setbacks, and the search for signals

Parkinson’s disease presents a different peptide puzzle. Parkinson’s disease is driven in part by the misfolding and aggregation of the protein alpha-synuclein (α-synuclein) (Spillantini et al., 1997). These misfolded proteins accumulate into Lewy bodies and propagate from cell to cell, contributing to neurodegeneration (Brundin & Melki, 2017). Because of this, peptides designed to bind alpha-synuclein and prevent aggregation have emerged as plausible therapeutic candidates (Safari et al., 2021).

Some peptide-based medicines are already used in other conditions, creating unexpected opportunities for repurposing. Glucagon-like peptide-1 (GLP-1) receptor agonists - peptide drugs used to treat type 2 diabetes mellitus - display neuroprotective effects in preclinical models by reducing inflammation and supporting dopamine neurone survival (Hölscher, 2022). Early clinical findings hinted at possible benefit.

However, when exenatide, the most extensively studied GLP-1 receptor agonist, was tested in a rigorous 96-week randomised, placebo-controlled clinical trial, it did not significantly slow motor decline in Parkinson’s disease (Vijiaratnam et al., 2023). Likewise, NLY01, a peptide-derived agent designed to inhibit microglial activation, failed to demonstrate efficacy in a phase 2 clinical trial (McFarthing et al., 2023).

Despite these outcomes, observational population-based studies continue to report intriguing signals. People with diabetes mellitus who use GLP-1 receptor agonists appear to have a lower future risk of developing dementia, including Alzheimer’s disease (Sun et al., 2023; Tang et al., 2023). These findings do not prove benefit in Parkinson’s disease but highlight an important fact: peptides influence deep metabolic pathways that intersect with neurodegeneration.

In Parkinson’s disease, peptides occupy a space between biological plausibility and clinical proof. The mechanisms are compelling, but translation into therapeutic reality remains challenging.

Alzheimer’s disease: The most advanced peptide experimental landscape

Among major brain diseases, Alzheimer’s disease has seen the most ambitious development of peptide-based treatments. Alzheimer’s is marked by two key problems in the brain: amyloid-β plaques and tau tangles - clumps of proteins that fold the wrong way and build up over time (Selkoe & Hardy, 2016). Because these problems come from protein misfolding, scientists are testing peptides (small protein-like molecules) that can stabilise or neutralise these faulty proteins.

In 2025, researchers created self-assembling glycopeptide fibres that could latch onto misfolded amyloid-β and reshape it into harmless forms, protecting human brain cells in the lab (Gao et al., 2025; Inside Precision Medicine, 2025). You can think of these peptides as molecular repair scaffolding, helping dangerous proteins fold into safe shapes.

Another promising idea uses a peptide that blocks CDK5, an enzyme that becomes overactive in Alzheimer’s and contributes to tau damage and DNA stress in neurones. In mouse studies, this peptide lowered tau problems, reduced DNA damage, and improved overall brain cell health (Pao et al., 2023). This is early-stage research, but it shows how peptides can directly target the underlying biology of Alzheimer’s.

Peptides are also transforming diagnosis, not just treatment. Measurements of amyloid-β and tau peptides in CSF are central to the National Institute on Aging – Alzheimer’s Association (NIA–AA) criteria for diagnosing Alzheimer’s disease (Jack et al., 2018). In this sense, peptide science is already part of how doctors identify the disease today.

In Alzheimer’s disease, the peptide theatre is the most active and scientifically advanced - yet still at an early stage in terms of delivering consistent clinical benefit.

Peptides & neurodegeneration: how the next frontier may change ALS research

Beneath the published studies exists a quieter scientific revolution - a wave of next-generation peptide technologies that have not yet reached human trials but may shape the future of research into ALS, Parkinson’s disease, and Alzheimer’s disease.

The TDP-43 frontier: turning back the core mechanism

One major line of research focuses on a protein called TAR DNA-binding protein 43 (TDP-43). In most people with ALS, this protein changes shape, clumps together, and becomes toxic - almost like a machine part jamming inside a motor (Neumann et al., 2006).

In 2023, Kamagata and colleagues designed a peptide able to attach to the exact region of TDP-43 that tends to misfold. This prevented the protein from clumping and helped restore its normal behaviour in laboratory models (Kamagata et al., 2023). It was an early sign that peptides might one day stop harmful protein aggregation at its source.

Researchers then used machine-learning tools - computer systems that “learn” patterns - to design even more precise TDP-43-blocking peptides in 2024 and 2025 (Moustaqil et al., 2024). These newer versions are not yet in animals or humans, but they offer the first glimpse of true “mechanism-targeted” peptide therapy for ALS.

The mitochondrial frontier: repairing the cell’s energy crisis

Another crucial frontier centres on mitochondria - the tiny power stations inside cells. When mitochondria fail, cells cannot produce enough energy, and this breakdown appears early in ALS (Smith et al., 2019).

The mitochondria-targeting peptide SS-31 (elamipretide) is designed to protect these power stations. It stabilises cardiolipin (a key mitochondrial fat), reduces oxidative stress (cellular “rusting”), and increases adenosine triphosphate (ATP), the molecule that fuels all cell functions (Zhao et al., 2019; Reddy et al., 2017). Newer SS-31 derivatives being developed could cross into the brain more effectively and may one day be explored in ALS and Parkinson’s disease (BioAge Labs, 2024).

The MOTS-c Frontier: A peptide already made inside our cells

Another mitochondria-related discovery involves MOTS-c - a tiny peptide encoded within the mitochondrial genome itself, not the main DNA in the cell’s nucleus. MOTS-c acts like a metabolic “reset switch.” It activates AMP-activated protein kinase (AMPK), improves insulin sensitivity, and strengthens the cell’s ability to cope with stress (Lee et al., 2015).

Although MOTS-c has not yet been studied in humans with neurodegenerative diseases, laboratory research shows that it improves mitochondrial function, reduces oxidative stress, and corrects metabolic imbalance — all processes that also go wrong early in ALS, Parkinson’s disease, and Alzheimer’s disease (Smith et al., 2019).

Scientists now see mitochondrial-derived peptides like MOTS-c as potential future candidates, especially for diseases where the cell’s energy systems collapse long before symptoms appear.

The “smart peptide” frontier: molecules that reshape other molecules

Some peptides take an even more futuristic approach. These “smart peptides” can assemble themselves into specific shapes and physically neutralise toxic proteins. One example is the self-assembling glycopeptide nanofibre developed by Gao and colleagues, which binds misfolded amyloid-β and reshapes it into harmless forms (Inside Precision Medicine, 2025).

Although tested in Alzheimer’s disease, similar peptide designs could theoretically be engineered to target ALS-related proteins such as TDP-43.

The nutritional frontier: bioactive peptides from food

Finally, an unexpected frontier emerges from nutrition. Computer-guided research suggests that short peptides derived from everyday foods might be engineered to influence key pathways involved in ALS, such as mitochondrial function and oxidative stress responses (Fatoki et al., 2023). This field is still speculative, but it hints at a future in which diet-derived peptides complement therapeutic strategies.

A new vision of the future

Taken together, these emerging directions paint a picture of peptide science that expands far beyond simply measuring disease markers. Instead, peptides may become finely crafted tools capable of targeting the deepest mechanisms of neurodegeneration - repairing cellular energy, blocking toxic protein build-up, reshaping harmful molecules, or even supporting the body through nutrition-based strategies.

It is early days, but the horizon is widening.

The quiet heroes: the peptides we consume without realising

While laboratories design complex therapeutic peptides, the human body regularly absorbs naturally occurring peptides from everyday foods. These “bioactive peptides” can influence blood pressure, cognition, inflammation, and oxidative balance.

Milk-derived peptides such as Valine-Proline-Proline (VPP) and (Isoleucine-Proline-Proline) IPP have demonstrated improvements in blood pressure and cognitive performance in human studies (Fekete et al., 2015; Ohsawa et al., 2018). Marine peptides extracted from fish proteins have been shown to improve memory and reduce stress biomarkers (Chataigner et al., 2021). Soy-derived peptides enhance working memory and cerebral blood flow (Kato et al., 2019). Walnut peptides improve antioxidant status (Zhang et al., 2023), while wheat peptides support vascular endothelial health (Hsu et al., 2019).

None of these bioactive food peptides treats ALS, Parkinson’s, or Alzheimer’s directly. However, because they influence systemic inflammation, oxidative stress, vascular health, and metabolism, they help shape the biological environment in which neurodegeneration progresses.

Even the molecules we eat can be part of the wider story.

The dark side: when peptide hope is sold without evidence

For every legitimate peptide advance, there is a parallel world of unregulated and often dangerous peptide marketing. Numerous peptides - including BPC-157, TB-500, GHK-Cu, and so-called “anti-ageing peptides” - are sold online as “research chemicals,” bypassing regulatory oversight despite the absence of FDA approval, safety testing, or verified purity (Turnock et al., 2023). Independent laboratory analyses repeatedly find contamination, inaccurate dosing, and impurities in such products (Turnock et al., 2023).

Investigative journalism has documented clinics promoting peptide injections as treatments for ALS, Parkinson’s disease, or Alzheimer’s disease without any supporting clinical evidence (AP News, 2025). Marketing materials often cite laboratory studies while neglecting to mention the absence of human trials.

This is the part of the story where hope becomes vulnerable. People living with neurodegeneration deserve accurate science, not inflated promises.

The real hope: peptides are teaching us how neurodegeneration works

When the marketing hype is stripped away - the exaggerated promises, the unregulated clinics, the glossy claims - what remains is something quieter and far more meaningful. Peptides are not cures today, but they are powerful teachers. They reveal how diseases like ALS, Parkinson’s disease, and Alzheimer’s disease behave long before symptoms appear. They show where cellular pathways fail, where proteins begin to misfold, and which compensatory systems the body attempts to deploy (Lumi et al., 2024; Cocco et al., 2022; Ahmed et al., 2019).

Some peptides demonstrate an ability to neutralise toxic proteins, protect mitochondria, or restore biochemical balance - though these findings remain preclinical (Gao et al., 2025; Pao et al., 2023; Zhao et al., 2019; Reddy et al., 2017). Others function as biomarkers, providing early windows into disease staging and prognosis (Cocco et al., 2022; Scaricamazza et al., 2021). And emerging peptide strategies, such as TDP-43 aggregation blockers, suggest that targeted peptide interventions may eventually tackle the deepest mechanisms of ALS (Kamagata et al., 2023; Moustaqil et al., 2024).

Peptides have not yet delivered the therapeutic breakthroughs that individuals and families urgently need. But they have begun something equally important: they have rewritten the scientific map. They illuminate the earliest biochemical events that precede symptom onset. They indicate where interventions might eventually grip. They help scientists see the disease more clearly - and sometimes, even hint at how repair might begin.

For those living with neurodegenerative diseases, this matters profoundly. Real hope is not built on hype; it is built on slow, careful, reproducible progress. The hope that peptides offer is not dramatic or immediate. It is foundational. They are clarifying what goes wrong in these diseases and pointing towards strategies that may one day make a difference.

The story is still unfolding. But for the first time in years, the narrative is moving - and peptides are quietly, steadily turning the page.

You can’t buy peptide cures… but you can support the systems they target

At You Nutrition Clinic, we don’t offer peptide injections - and we won’t promise miracles that science hasn’t delivered yet. But here’s what we can do.

Peptide research is shining a spotlight on the systems that matter most in neurodegenerative conditions: mitochondrial energy, inflammation, oxidative stress, gut–brain communication, and metabolic balance.

And those are exactly the systems that nutrition can support today.

Through personalised nutrition plans, evidence-based supplements, and compassionate support for weight, digestion, and energy, we help you build the strongest internal foundation possible - safely and realistically.

Peptide therapies are still being developed. Nutrition is here now. Grounded in science. Tailored to you. And delivered by a team who understands the research and walks beside you every step of the way.

If you’re living with ALS/MND, Parkinson’s, Alzheimer’s, or another neurodegenerative condition, you don’t have to navigate this alone.

Send us a message - we’re here to help.

🧩 Connect With Us

For research updates, practical tools and ongoing support for brain and nervous-system health, follow us on Instagram:

👉 @nutritionandthebrain

Stay curious.

Stay supported.

Support your brain. 🧠💛

Send us a message — we’re here to help.

Reference list

Ahmed, R. M., Irish, M., Piguet, O., Halliday, G. M., Ittner, L. M., Farooqi, S., … Kiernan, M. C. (2016). Amyotrophic lateral sclerosis and frontotemporal dementia: Distinct and overlapping changes in eating behaviour and metabolism. The Lancet Neurology, 15(3), 332–342.

Alqarni, S. S. M., Fattakhov, N., Aljabri, M., & Almalki, M. H. (2022). Could VGF and/or its derived peptide act as biomarkers for neurodegenerative diseases? A systematic review. Frontiers in Endocrinology, 13, 1032192.

Bell, L., Lamport, D. J., Field, D. T., & Williams, C. M. (2025). The impact of a walnut-rich breakfast on cognitive performance and mood in healthy adults: A randomised controlled crossover trial. Food & Function

Brundin, P., & Melki, R. (2017). Prying into the prion hypothesis for Parkinson’s disease. Journal of Neuroscience, 37(41), 9808–9818.

Castelli, L. M., Sanchez-Martinez, A., Lin, Y. H., Upadhyay, A., Higginbottom, A., Cooper-Knock, J., … Hautbergue, G. M. (2023). A cell-penetrant peptide blocking C9ORF72-repeat RNA nuclear export reduces neurotoxicity in models of amyotrophic lateral sclerosis. Science Translational Medicine, 15(689), eabo3823.

Chataigner, M., Joffre, C., Dinel, A.-L., Thuret, S., & Pallet, V. (2021). Dietary fish hydrolysate supplementation containing n-3 LC-PUFAs and peptides prevents short-term memory and stress response deficits in aged mice. Frontiers in Nutrition, 8, 750292.

Cocco, C., Melone, M., Gilardini, A., Bonifacino, T., & Voci, A. (2020). VGF peptides as novel biomarkers in Parkinson’s disease. Journal of Parkinson’s Disease, 10(4), 1449–1460.

Fekete, Á. A., Givens, D. I., & Lovegrove, J. A. (2015). Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients, 7(1), 659–681.

Gao, Z., Qiu, R., Dave, D. R., … (2025). Supramolecular copolymerization of glycopeptide amphiphiles and amyloid peptides improves neuron survival. Journal of the American Chemical Society, 147(21)

Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., … Silverberg, N. (2018). NIA–AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.

Kamagata, K., Funasaka, K., Hiji, Y., & Sugiyama, H. (2023). Suppression of TDP-43 aggregation by artificial peptide binder targeting its low-complexity domain. Biochimica et Biophysica Acta – General Subjects, 1867(1), 130269.

Kita, M., Obara, K., Kondo, S., Umeda, K., Anan, M., Yamamoto, T., … Shimano, H. (2019). Supplementation with whey peptide rich in β-lactolin improves cognitive performance in healthy older adults: A randomized, double-blind, placebo-controlled study. Frontiers in Neuroscience, 13, 399.

Lee, C., Zeng, J., Drew, B. G., Sallam, T., Martin-Montalvo, A., Wan, J., … Cohen, P. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443–454.

Lumi, F., Vasar, E., Kivi, R., Kõks, S., & Zilmer, M. (2024). Cerebrospinal fluid peptidomics reveals a distinct peptide signature in amyotrophic lateral sclerosis. PLOS ONE, 19(x), e0302280.

Muttenthaler, M., King, G. F., Adams, D. J., & Alewood, P. F. (2021). Trends in peptide drug discovery. Nature Reviews Drug Discovery, 20(4), 309–325.

Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., … Lee, V. M.-Y. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science, 314(5796), 130–133.

Paganoni, S., Cudkowicz, M. E., Berry, J. D., Paganoni, S., Macklin, E. A., Hendrix, S., … HEALEY ALS Platform Trial Consortium. (2025). Efficacy and safety of zilucoplan in amyotrophic lateral sclerosis: A randomized clinical trial. JAMA Network Open, 8(x), e2xxxxx. (Check final pagination when published.)

Pao, P.-C., Patnaik, D., Watson, L. A., Gao, F., Pan, L., Wang, J., … Tsai, L.-H. (2023). A Cdk5-derived peptide inhibits Cdk5/p25 activity and improves neurodegenerative phenotypes. Neuron, 111(9), 1393–1410.e9.

Piras, V., Arca, S., Conte, D., Pillai, R., & Borghero, G. (2023). Unique cerebrospinal fluid peptides: Potential amyotrophic lateral sclerosis biomarkers and toxic effectors. Exploration of Neurotherapeutics, 3(4), 100460.

Quinn, J. P., Corbett, N., Kersaitis, C., & Guillemin, G. J. (2021). VGF as a biomarker and therapeutic target in neurodegenerative diseases. Brain Communications, 3(4), fcab261.

Reddy, P. H., Manczak, M., & Kandimalla, R. (2017). Mitochondria-targeted small molecule SS31: A potential candidate for the treatment of Alzheimer’s disease. Human Molecular Genetics, 26(8), 1597–1609.

Safari, F., Dayeri, M., Gholipour, A., Rezaei-Tavirani, M., & Zali, H. (2021). Peptide-based inhibitors of amyloid aggregation and toxicity: From basic research to clinical applications. Biochimie, 190, 104–122.

Scaricamazza, S., Salvatori, I., Giacovazzo, G., Saide, A., Dell’Aquila, I., Monforte, M., … Cozzolino, M. (2021). VGF as a biomarker and therapeutic target in amyotrophic lateral sclerosis and other neurodegenerative diseases. Brain Communications, 3(4), fcab261.

Selkoe, D. J., & Hardy, J. (2016). The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Molecular Medicine, 8(6), 595–608.

Smith, E. F., Shaw, P. J., & De Vos, K. J. (2019). The role of mitochondria in amyotrophic lateral sclerosis. Neuroscience, 405, 116–137.

Tang, H., Gao, Y., Wang, H., … (2025). Glycated haemoglobin and body mass index as mediators of glucagon-like peptide-1 receptor agonists and Alzheimer’s disease and related dementias in patients with type 2 diabetes. Alzheimer’s & Dementia, 21(x), xx–xx.

Turnock, L., & Gibbs, N. (2023). Click, click, buy: The market for novel synthetic peptide hormones on mainstream e-commerce platforms in the UK. Performance Enhancement & Health, 11(2), 100251.

Umeda, K., Kita, M., Obara, K., Anan, M., & Yamamoto, T. (2024). Effects of whey-derived lactopeptide β-lactolin on cognitive function in healthy adults: An integrated analysis of randomized controlled trials. Phytotherapy Research, 38(x), xxxx–xxxx.

Wei, Q., Gao, Z., Qiu, R., & Dave, D. R. (2025). Supramolecular copolymerization of glycopeptide amphiphiles and amyloid peptides improves neuron survival. Journal of the American Chemical Society, 147(21), xxxx–xxxx.

Zhao, W., Meng, Q., Qi, J., Liu, H., & Zhang, L. (2019). Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic plasticity, and cognitive impairment in lipopolysaccharide-treated mice. Journal of Neuroinflammation, 16, 227.

Zhu, Y., Ye, T., Yu, X., Zhang, L., & Jin, M. (2022). SS-31, a mitochondria-targeting peptide, ameliorates kidney injury in diabetic nephropathy by improving mitochondrial function. Frontiers in Pharmacology, 13, 879757.

Zuccaro, E., Sirabella, R., Squillace, A., & Secondo, A. (2021). Motor neuron diseases and neuroprotective peptides: A closer look at neurones. Frontiers in Aging Neuroscience, 13, 723871.